Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study

Vincenzo Oliva\textsuperscript{a}, Giuseppe Fanelli\textsuperscript{a,b}, Manuel Zamparini\textsuperscript{c}, Cristina Zarbo\textsuperscript{c}, Matteo Rocchetti\textsuperscript{d,e}, Letizia Casiraghi\textsuperscript{d,e}, Fabrizio Starace\textsuperscript{f}, Alessandra Martinelli\textsuperscript{g,h}, Alessandro Serretti\textsuperscript{a}, Giovanni de Girolamo\textsuperscript{c} and the DiAPASon Consortium

Antipsychotic polypharmacy (APP) in patients with schizophrenia spectrum disorders (SSDs) is usually not recommended, though it is very common in clinical practice. Both APP and SSDs have been linked to worse health outcomes and decreased levels of physical activity, which in turn is an important risk factor for cardiovascular diseases and premature mortality. This real-world, observational study aimed to investigate antipsychotic prescribing patterns and physical activity in residential patients and outpatients with SSDs. A total of 620 patients and 114 healthy controls were recruited in 37 centers across Italy. Each participant underwent a comprehensive sociodemographic and clinical evaluation. Physical activity was monitored for seven consecutive days through accelerometer-based biosensors. High rates of APP were found in all patients, with residential patients receiving more APP than outpatients, probably because of greater psychopathological severity. Physical activity was lower in patients compared to controls. However, patients on APP showed trends of reduced sedentariness and higher levels of light physical activity than those in monopharmacy. Rehabilitation efforts in psychiatric residential treatment facilities were likely to result in improved physical activity performances in residential patients. Our findings may have important public health implications, as they indicate the importance of reducing APP and encouraging physical activity. \textit{Int Clin Psychopharmacol} 38: 28–39 Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

International Clinical Psychopharmacology 2023, 38:28–39

Keywords: actigraph, antipsychotics, monopharmacy, physical fitness, polypharmacy, psychiatric residential treatment facilities, psychosis, psychotropic drugs, rehabilitation, wearable accelerometer-based biosensor

\textsuperscript{a}Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy, \textsuperscript{b}Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands, \textsuperscript{c}Unit of Epidemiological and Evaluation Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, \textsuperscript{d}Department of Mental Health and Dependence, ASST of Pavia, \textsuperscript{e}Department of Brain and Behavioral Sciences, University of Pavia, Pavia, \textsuperscript{f}Department of Mental Health and Dependence, AUSL of Modena, Modena, \textsuperscript{g}Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona and \textsuperscript{h}Unit of Clinical Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

Correspondence to Alessandro Serretti, MD, PhD, Department of Biomedical and Neuromotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy
Tel: +39 051 658 4233; e-mail: alessandro.serretti@unibo.it

Received 22 June 2022 Accepted 26 July 2022

Introduction

Many drug utilization studies have found significant variability in prescribing patterns of psychotropic drugs and have highlighted high rates of polypharmacy (de Girolamo \textit{et al.}, 1987; Gallego \textit{et al.}, 2012). High frequencies of polypharmacy and off-label prescriptions have been consistently found in patients in treatment at mental health services in Italy (Bellantuono \textit{et al.}, 1981; Muscettola \textit{et al.}, 1987; Muscettola \textit{et al.}, 1991; Carton \textit{et al.}, 2015). In particular, antipsychotic polypharmacy (APP) is prescribed to a substantial proportion of patients suffering from severe mental disorders, approaching 23% in Europe (Gallego \textit{et al.}, 2012). Up to 44.4% of patients with a schizophrenia spectrum disorder (SSD) receive a combination of antipsychotics, whereas at least 24.4% receive three or more antipsychotics (Fisher \textit{et al.}, 2014). However, the clinical utility of APP is often debated. In selected clinical conditions, including treatment-resistant schizophrenia, antipsychotic-induced hyperprolactinemia and metabolic disturbances in patients receiving clozapine, APP may be indicated (Correll \textit{et al.}, 2009; Esteves \textit{et al.}, 2015; Cooper \textit{et al.}, 2016; De Berardis \textit{et al.}, 2020; Caliskan \textit{et al.}, 2021). Nevertheless, the increased risk of adverse events, drug-drug interactions, decreased adherence to complex drug regimens and consequent risk of early relapse, as well as the higher costs associated with polypharmacy should lead clinicians to exercise caution when using multiple medications at the same time, particularly in the case of long-term treatments (Galling \textit{et al.}, 2017; Gundogmus \textit{et al.}, 2021). The use of APP in clinical practice may sometimes be justified also by the desire to improve the therapeutic response (Lahteenvuо and Tiibonen, 2021). However,
even in this case, it is known that particular care must be taken when combining a partial dopaminergic agonist and a full D2 receptor antagonist, which may increase the risk of clinical relapse or worsening of psychotic symptoms (Lippi et al., 2022). The relevant gap between evidence and routine practice, therefore, needs to be further investigated. Of particular interest are the prescription patterns in psychiatric residential treatment facilities, where previous studies have shown that polypharmacy was common, with an average of 2.7 drugs prescribed for each treated patient (Tomasi et al., 2006). It is necessary to understand to which extent different treatment settings (outpatient care vs. residential care) are associated with different prescription patterns.

Several studies have also indicated that both severe psychoses and antipsychotic use are associated with lower levels of physical activity and consequently lower levels of physical fitness. Indeed, a meta-analysis has shown that people with severe mental disorders were significantly more sedentary and less likely to meet physical activity targets established by international guidelines than healthy controls (Vancampfort et al., 2017). Even at a young age, patients taking antipsychotic drugs are less physically active and have a compromised body balance compared to adolescents not treated with antipsychotics (Vancampfort et al., 2016), and illness chronicity has been identified as a worsening factor in physical activity (Walther et al., 2015).

Low levels of physical activity and a lower physical fitness are important risk factors for cardiovascular diseases and premature mortality (Kodama et al., 2009), and this becomes even more relevant in patients with psychosis, who have higher standardized mortality rates compared to the general population (Simon et al., 2018). Physical activity may help reduce the risk of weight gain and metabolic syndrome, as well as tobacco and substance use (Mittal et al., 2017), which are often observed in people with schizophrenia or treated with antipsychotics. Furthermore, it is well known that physical exercise can improve cognitive functioning and facilitate neurogenesis in areas of the brain affected by psychosis (Firth et al., 2017). For this reason, it is important to explore physical activity levels in patients with SSDs to enable targeted and preventive interventions. The largest part of previous studies investigating the relationship between severe mental disorders and physical activity was based on retrospective physical activity self-reports. Although such measures are related to a series of advantages (e.g., limited costs and ease of implementation across a large variety of populations and settings), physical activity tends to be misreported, with much higher or lower amounts of activity being recalled than those reported in studies using objective measures (Prince et al., 2008). The inaccuracy of self-reports may be even more exaggerated in people with SSDs because of particularly common recall errors (Firth et al., 2018). The recent availability of wearable devices allows real-time detection of physical activity and may much improve knowledge and management of rehabilitation programs.

Accelerometers are small and non-invasive, and they can measure physical activity by quantifying movement with sampling frequencies that can reach 100 observations per second (Hz) while providing an objective assessment of movement-based physical activity across the entire intensity spectrum (from zero to maximal exertion). The close investigation of physical activity using objective measures can allow the collection of valuable data to study the relationship between antipsychotic prescribing patterns and physical activity (Chen et al., 2016; Wee et al., 2019).

The present study will therefore investigate antipsychotic prescribing patterns and physical activity measurements conducted with wearable accelerometer-based biosensors in a sample of people with SSDs.

**Materials and methods**

From October 2020 to October 2021, 620 patients (i.e. 313 residential patients (RPs) and 307 outpatients) with a diagnosis of an SSD were recruited in 37 Departments of Mental Health (DMH) or psychiatric residential treatment facilities across Italy as part of the DAItly time use, Physical Activity, quality of care and interpersonal relationships in patients with Schizophrenia spectrum disorders (DiAPASon) project (de Girolamo et al., 2020). We included patients with a Diagnostic and Statistical Manual of mental disorders (DSM)-5-based diagnosis of any SSDs (American Psychiatric Association, 2013) who were 20–55 years old and able to speak and write in Italian. We excluded patients who were unable to provide informed consent or who reported severe cognitive deficits (i.e. a Mini-Mental State Examination corrected score lower than 24), a recent diagnosis of substance use disorder according to DSM-5 criteria, a history of clinically significant head injury or cerebrovascular/neurological disease. In each study center, clinicians invited their patients to enter the study. Participants were provided with detailed information about the study and had the opportunity to ask questions. Some of the assessment tools were administered by the treating clinician, whereas research assistants helped patients to complete self-reported questionnaires.

In the same period, 114 healthy controls were recruited from the general population through advertisements, both on the project website and social networks, to take part in the actigraphy study. The healthy controls had no history of psychiatric disorders according to DSM-5 criteria and were excluded based on the same criteria used for the recruitment of patients. The healthy controls were paired for age and sex with the clinical sample who performed the accelerometer-based physical activity measurement.

The accelerometer-based physical activity measurement was undertaken in 10 of the participating centers due to organizational and logistic problems which prevented the implementation of the biosensor study in the remaining study sites. The monitoring was preceded by a briefing session in which the research assistant gave instructions about the procedures and how to effectively perform
them and was followed by a debriefing section in which the same research assistant collected information on study acceptability and feasibility. During the debriefing session, outpatients and healthy controls received €25.00 for travel expense reimbursement.

The DiAPASon study has been approved by the ethical committees of the three main participating centers, which are, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli (31/07/2019; no. 211/2019), Area Vasta Emilia Nord (25/09/2019; no. 0025975/19), Pavia (02/09/2019, no. 20190075685), and by the ethical committees of all the other participating sites.

**Assessment of clinical variables**

For each recruited patient, we completed a sociodemographic and clinical assessment, and several validated clinical scales were administered; for details see the study protocol (de Girolamo et al., 2020). The 24-item Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962; Morosini and Casacchia, 1995) was used to assess the presence and severity of psychopathology; BPRS items were rated on a seven-point scale ranging from 1 (not present) to 7 (extremely severe). Negative symptoms severity was assessed using the Brief Negative Symptom Scale (BNSS) (Strauss et al., 2012; Mucci et al., 2015), a 13-item instrument designed for the evaluation of blunted affect, alogia, asociality, anhedonia and avolition (from 0 – not present to 6 – severe deficit). For both BPRS and BNSS, higher total scores denote higher severity of symptomatology. The 43-item Specific Levels of Functioning Scale (SLOF) (Montemagni et al., 2015) was used for the assessment of psychosocial functioning. The SLOF is a multidimensional behavioral survey comprising six subscales: physical functioning, personal care skills, interpersonal relationships, social acceptability, activities of community living, and work skills. The SLOF items were rated on a five-point scale ranging from 1 to 5. Higher scores denote the higher functioning of the patient. The self-reported WHO Disability Assessment Schedule (WHODAS) 2.0 (Federici et al., 2009; Gold, 2014) was used to assess disability across six functional domains: that is, cognition, mobility, self-care, getting along, life activities and participation. The items of the WHODAS 2.0 range from 0 to 4, and higher scores indicate a higher functional disability. The Charlson Comorbidity Index (CCI) (Charlson et al., 1987) was used to assess the somatic comorbidity of all participants. The CCI consisted of 19 items corresponding to different medical comorbid conditions; the total score consists of the sum of the conditions presented, with higher scores indicating more severe comorbid conditions.

**Assessment of physical activity**

Physical activity was monitored through the multisensor device Actigraph GT9X Link, which is a validated triaxial accelerometer that includes a gyroscope, magnetometer, secondary accelerometer and Bluetooth capability manufactured by ActiGraph, LLC (https://actigraphcorp.com/actigraph-link/). The Actigraph GT9X provides reliable data about metabolic equivalents, activity intensity and sleep efficiency/quality. The Actigraph was worn on the non-dominant wrist for seven consecutive days.

**Data management**

Upon the return of both devices, data were uploaded using ActiLife (Actigraph, Pensacola, Florida, USA) and saved in raw format as GT3X+ files. Individual ActiGraph’s.gt3x files were processed using the GGIR R package (Migueles et al., 2019) (with default settings). To estimate the Euclidean norm of the acceleration in x/y/z axes and to separate out the activity-related component of the acceleration signal, we removed one gravitational unit from the vector magnitude (with remaining negative values truncated to zero) obtaining Euclidean Norm Minus One (ENMO). To describe the overall level and distribution of physical activity intensity, we combined the sample level data into 60 s epochs for summary data analysis, maintaining the average vector magnitude value over the epoch. To represent the distribution of time spent by an individual in different levels of physical activity intensity, we generated an empirical cumulative distribution function from all available 60 s epochs. Non-wearing epochs, defined as stationary periods, were estimated using a 60 min window and the default GGIR algorithm and removed (no data imputation was performed) (van Hees et al., 2013). A valid day was defined as having at least 10 h of wearing time, and a valid subject was defined as having at least four valid days.

For each epoch, oxygen consumption (VO₂) was estimated through the formula:

\[
\text{VO}_2 = 0.901 \cdot \text{ENMO}^{0.534}
\]

If VO₂ was less than 3.0, we set to floor of 3.0 and computed the metabolic equivalent of task (MET) as:

\[
\text{MET} = \frac{\text{VO}_2}{3.5}
\]

One MET is defined as the energy used when resting or sitting still (i.e. an activity that has a value of four METs means that the subject is consuming four times the energy than would if he/she was sitting still).

To get a categorical measure of physical activity intensity in each epoch, we finally categorized the number of METs as follows (Hildebrand et al., 2014):

1. \( \text{METs} \leq 1.5 \) = sedentary;
2. \( 1.5 < \text{METs} < 3.0 \) = light;
3. \( 3.0 \leq \text{METs} < 6.0 \) = moderate;
4. \( \text{METs} \geq 6.0 \) = vigorous.
**Statistical analyses**

Frequencies and percentages for categorical variables and means and SDs for continuous variables were computed. Chi-squared or Fisher’s exact tests were used according to the nature of the data to compare categorical variables between groups. The distribution of continuous variables was established using Kolmogorov–Smirnov normality tests. T-tests and ANOVA, or the nonparametric Mann–Whitney and Kruskal–Wallis tests, were used for continuous variables as appropriate. Bonferroni post hoc tests were also performed to identify which pairs of means were statistically different when ANOVA or Kruskal–Wallis tests were significant. Effect sizes were estimated with Phi coefficient for categorical variables and Cohen’s d (standardized mean difference) for continuous variables. All analyses were carried out using SPSS software (IBM, Version 27.0) and SAS Studio (SAS Institute Inc. 2015), with the statistical significance level set at 0.05, given the exploratory nature of this study.

**Results**

**Sociodemographic and clinical characteristics of the sample**

The sociodemographic and clinical features of the sample are reported in detail in Table 1. Patients with SSDs and healthy controls were comparable with respect to age but differed with respect to the other sociodemographic variables considered. In particular, controls included more female subjects, they were more likely to cohabit, have higher education, and be involved in work activities than patients.

Looking at the patient groups, patients on APP were more likely to have no partners, had a longer duration of illness and spent more time in psychiatric hospitalizations than patients on antipsychotic monopharmacy (APM). Furthermore, significant differences were found in BPRS and BNSS scores between patients on APM and APP, with the latter showing higher psychopathologic and negative symptoms severity. Psychosocial functioning, as measured by SLOF, was significantly better in patients on APM than on APP. Concerning patients’ physical health, patients on APM and APP did not differ in terms of BMI, waist circumference and CCI. Regarding smoking habits, patients on APP were more likely smokers than those on APM, with a great number of cigarettes per day smoked.

Treatment settings (e.g. residential or outpatient) may impact both prescription patterns and physical activity. Therefore, Table 2 reports the sociodemographic and clinical characteristics of the sample with respect to the treatment setting. Regarding psychopathology, significant differences were found in BPRS (U = 80.977; P < 0.001) and BNSS (U = 83.578; P < 0.001) scores between outpatients and residential patients, with the latter showing higher psychopathological and negative symptoms severity. Psychosocial functioning, as

---

**Table 1 Sociodemographic and clinical features of patients (on antipsychotic mono- and polypharmacy) and healthy controls**

| Variables                  | Patients on antipsychotic monopharmacy N=316 (52.1%) | Patients on antipsychotic polypharmacy N=291 (47.9%) | χ²/U Effect size | P value* | Healthy controls N=114 |
|----------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------|----------|------------------------|
| Sex, N (%)                 |                                                     |                                                     |                 |          |                        |
| Male                       | 215 (68.0%)                                         | 202 (69.4%)                                         | 0.134           | 0.015    | 715                    |
| Age (mean, SD)             | 41.2 (9.8)                                          | 41.7 (9.3)                                          | 89.763          | 0.005    | 0.547                  |
| Marital status, N (%)      |                                                     |                                                     |                 |          |                        |
| Single                     | 259 (82.0%)                                         | 266 (91.4%)                                         | 16.086          | 0.001    | 0.052                  |
| Married or cohabiting      | 34 (10.8%)                                          | 8 (2.8%)                                            | 77              | 0.115    | 0.005                  |
| Divorced or widowed        | 23 (73%)                                            | 17 (5.8%)                                           | 7               | 0.005    | 0.005                  |
| Education (mean, SD)       | 11.9 (3.1)                                          | 11.4 (3.1)                                          | 84.345          | 0.001    | 0.052                  |
| Working status, N (%)      |                                                     |                                                     |                 |          |                        |
| Working                    | 65 (20.6%)                                          | 58 (19.9%)                                          | 0.041           | 0.008    | 0.980                  |
| Studying                   | 18 (5.7%)                                           | 17 (5.8%)                                           | 8               | 0.005    | 0.980                  |
| Not working/studying       | 233 (73.7%)                                         | 216 (74.2%)                                         | 2               | 0.005    | 2 (1.8%)               |
| BMI (mean, SD)             | 27.9 (5.4)                                          | 27.6 (5.6)                                          | 86.029          | 0.004    | 0.259                  |
| Waist circumference (mean, SD) | 100.8 (20.5)                                      | 99.8 (23.5)                                         | 87.061          | 0.045    | 0.689                  |
| Smokers, N (%)             | 155 (49.1%)                                         | 175 (60.6%)                                         | 8.056           | 0.005    | 0.005                  |
| Smoking (cigarettes per day)| 7.8 (10.0)                                         | 10.4 (11.0)                                         | 94.956          | 0.247    | 0.001                  |
| (mean, SD)                 |                                                     |                                                     |                 |          |                        |
| CCI (mean, SD)             | 0.7 (1.1)                                           | 0.8 (1.3)                                           | 89.895          | 0.083    | 0.452                  |
| Illnessduration (mean, SD) | 17.2 (9.3)                                          | 19.5 (9.6)                                          | 94.643          | 0.243    | 0.004                  |
| Lifetime duration of psychiatric hospitalizations, N (%) |                                                     |                                                     |                 |          |                        |
| <1 year                    | 176 (55.7%)                                         | 108 (37.1%)                                         | 31.041          | 0.001    | <0.001                 |
| 1–5 years                  | 84 (26.5%)                                          | 77 (26.5%)                                          | NA              |          | NA                     |
| >5 years                   | 56 (17.7%)                                          | 106 (36.4%)                                         | NA              |          | NA                     |
| BPRS (mean, SD)            | 43.8 (12.9)                                         | 49.6 (16.9)                                         | 97.526          | 0.386    | <0.001                 |
| BNSS (mean, SD)            | 20.9 (14.9)                                         | 24.9 (16.3)                                         | 95.191          | 0.256    | 0.002                  |
| SLOF (mean, SD)            | 181.8 (22.2)                                        | 169.6 (36.0)                                        | 77.892          | 0.408    | <0.001                 |
| WHODAS 2.0 (mean, SD)      | 12.6 (9.1)                                          | 13.2 (9.6)                                          | 90.007          | 0.064    | 0.475                  |

*aChi-square test for categorical variables, Mann–Whitney-U test for continuous variables.  
*bFor these variables, healthy controls are significantly (P<0.05) different from patients.  
BPRS, Brief Psychiatric Rating Scale; BNSS, Brief Negative Symptom Scale; CCI, Charlson Comorbidity Index; N, number; SLOF, Specific Levels of Functioning Scale; WHODAS 2.0, WHO Disability Assessment Schedule.*

---

Copyright © 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Table 2  Sociodemographic and clinical features of outpatients and residential patients

| Variables                          | Outpatients N=307 (49.5%) | Residential patients N=313 (50.5%) | \(\chi^2/U\) | Effect size | P value* |
|-----------------------------------|--------------------------|-----------------------------------|-------------|------------|----------|
| Sex, N (%)                        |                          |                                   |             |            |          |
| Male                              | 202 (65.8%)              | 220 (70.3%)                       | 1.437       | 0.048      | 0.231    |
| Age (mean, SD)                    | 41.7 (9.2)               | 41.0 (9.7)                        | 97.110      | 0.074      | 0.423    |
| Marital status, N (%)             |                          |                                   |             |            |          |
| Single                            | 263 (85.7%)              | 271 (86.9%)                       | 11.468      | 0.136      | 0.003    |
| Married or cohabiting             | 30 (9.8%)                | 13 (4.2%)                         |             |            |          |
| Divorced or widowed               | 14 (4.6%)                | 28 (9.0%)                         |             |            |          |
| Education (mean, SD)              | 11.9 (3.0)               | 11.5 (3.2)                        | 98.917      | 0.129      | 0.115    |
| Working status, N (%)             |                          |                                   |             |            |          |
| Working                           | 90 (29.3%)               | 38 (12.2%)                        | 31.469      | 0.226      | <0.001   |
| Not working/studying              | 21 (6.8%)                | 14 (4.5%)                         |             |            |          |
| BMI (mean, SD)                    | 28.6 (6.0)               | 26.9 (4.9)                        | 103.564     | 0.310      | <0.001   |
| Waist circumference (mean, SD)    | 103.5 (22.2)             | 99.5 (15.9)                       | 101.300     | 0.207      | <0.001   |
| Smokers, N (%)                    | 142 (46.4%)              | 196 (62.8%)                       | 16.799      | 0.011      | 0.374    |
| Smoking (cig/day) (mean, SD)      | 42.6 (11.9)              | 26.3 (8.1)                        | 87.488      | 0.034      | <0.001   |
| CCI (mean, SD)                    | 0.6 (1.1)                | 0.9 (1.3)                         | 89.392      | 0.249      | 0.002    |
| Illness duration (mean, SD)       | 18.1 (9.4)               | 18.3 (9.6)                        | 95.082      | 0.021      | 0.859    |
| Lifetime duration of psychiatric hospitalizations, N (%) | | | | | |
| <1 year                           | 240 (78.2%)              | 53 (17.0%)                        | 235.780     | 0.617      | <0.001   |
| 1–5 years                         | 42 (13.7%)               | 122 (38.1%)                       |             |            |          |
| >5 years                          | 25 (8.1%)                | 137 (43.9%)                       |             |            |          |
| BPRS (mean, SD)                   | 42.6 (11.9)              | 51.0 (16.2)                       | 80.977      | 0.591      | <0.001   |
| BNSS (mean, SD)                   | 19.3 (13.9)              | 28.3 (16.6)                       | 83.578      | 0.457      | <0.001   |
| SLOF (mean, SD)                   | 183.2 (18.6)             | 174.3 (22.6)                      | 106.030     | 0.430      | <0.001   |
| WHO-DAS 2.0 (mean, SD)            | 13.4 (9.7)               | 12.5 (8.7)                        | 97.985      | 0.098      | 0.386    |

*aChi-square test for categorical variables, Mann–Whitney-U test for continuous variables.

BPRS, Brief Psychiatric Rating Scale; BNSS, Brief Negative Symptom Scale; CCI, Charlson Comorbidity Index; N, number; SLOF, Specific Levels of Functioning Scale; WHO-DAS 2.0, WHO Disability Assessment Schedule.

Table 3  Pattern of prescription in the whole sample and differences between outpatients and residential patients

| Drug category                        | N of patients receiving any drugs from each class (%) | Mean N of drugs from each class (SD) |
|--------------------------------------|-------------------------------------------------------|-------------------------------------|
|                                      | N of patients                                        | Residential patients                |
|                                      | N=620                                                 | N=307                               | N=313                               |
|                                      | P valueb                                              | P valueb                            |
|                                      | Residential patients                                  | P valueb                            |
|                                      | N=620                                                 | N=307                               | N=313                               |                                      |
| Antipsychotics (FGAs, SGAs, or clozapine) | 607 (97.9%)                                           | 301 (98.1%)                         | 306 (97.8%)                         | 0.806                                 |
|                                      | 1.6 (0.8)                                             | 1.4 (0.7)                           | 1.8 (0.9)                           | <0.001                                |
|                                      | 1–7+                                                  | 1–4+                                |
| FGAs                                 | 233 (37.6%)                                           | 95 (30.9%)                          | 138 (44.1%)                         | <0.001                                |
|                                      | 1.2 (0.5)                                             | 1.1 (0.4)                           | 1.2 (0.5)                           | 0.040                                 |
|                                      | 1–4+                                                  | 1–7+                                |
| SGAs                                 | 433 (69.6%)                                           | 229 (74.6%)                         | 204 (65.2%)                         | 0.011                                 |
|                                      | 1.2 (0.5)                                             | 1.2 (0.4)                           | 1.3 (0.5)                           | 0.034                                 |
|                                      | 1–3                                                  | 1–4+                                |
| Clozapine                            | 154 (24.8%)                                           | 48 (15.6%)                          | 106 (33.9%)                         | <0.001                                |
|                                      | NA                                                   | NA                                  | NA                                  | NA                                    |
| Antidepressants                      | 160 (25.8%)                                           | 61 (19.9%)                          | 99 (31.6%)                          | <0.001                                |
|                                      | 1.1 (0.4)                                             | 1.1 (0.3)                           | 1.2 (0.4)                           | 0.406                                 |
|                                      | 1–3                                                  | 1–4+                                |
| Antipsychotics (FGAs, SGAs, or clozapine) | 171 (27.6%)                                           | 90 (29.3%)                          | 81 (25.9%)                          | 0.338                                 |
|                                      | 1.1 (0.3)                                             | 1.1 (0.3)                           | 1.1 (0.3)                           | 0.628                                 |
|                                      | 1–3                                                  | 1–4+                                |
| Benzodiazepines                      | 333 (53.7%)                                           | 119 (38.8%)                         | 214 (68.4%)                         | <0.001                                |
|                                      | 1.2 (0.5)                                             | 1.1 (0.3)                           | 1.4 (0.6)                           | <0.001                                |
|                                      | 1–4+                                                  | 1–7+                                |

*aChi-square test.

bMann–Whitney-U test.

FGAs, first-generation antipsychotics; N, number; SGAs, second-generation antipsychotics.

measured by SLOF, was significantly better in outpatients than in residential patients (U = 106.030; P < 0.001). Finally, outpatients showed significantly shorter lifetime hospitalization duration than outpatients (\(\chi^2 = 235.780; P < 0.001\)).

The two groups in the number of cigarettes per day smoked (U = 87.488; P = 0.374).

Table 3 shows the pattern of prescription in the whole sample and the differences between outpatients and residential patients. Overall, 607 patients (97.9%) in the whole sample had a prescription of at least one antipsychotic, with second-generation antipsychotics (SGAs) being the most prescribed ones (69.8%). No difference was found in the overall prescription of antipsychotics between outpatients and residential patients, whereas significant differences were found for different subclasses of antipsychotics, with outpatients being more frequently prescribed SGAs and residential patients more frequently prescribed first-generation antipsychotics (FGAs).

Psychotropic drug prescription

Table 3 shows the pattern of prescription in the whole sample and the differences between outpatients and residential patients. Overall, 607 patients (97.9%) in the whole sample had a prescription of at least one antipsychotic, with second-generation antipsychotics (SGAs) being the most prescribed ones (69.8%). No difference was found in the overall prescription of antipsychotics between outpatients and residential patients, whereas significant differences were found for different subclasses of antipsychotics, with outpatients being more frequently prescribed SGAs and residential patients more frequently prescribed first-generation antipsychotics (FGAs).
Moreover, residential patients were significantly more likely to be on APP (number of drugs prescribed) and receive clozapine than outpatients. The second most prescribed psychotropic drug category in the whole sample was benzodiazepines (53.7%), with residential patients being the more prescribed group. A lower percentage of patients in the whole sample were prescribed antidepressants (27.6%) or mood stabilizers (25.8%). Residential patients more frequently received mood stabilizers than outpatients, while no difference was found between the two groups of patients with respect to antipsychotics.

The different prescription patterns of APM and APP, with respect to FGAs and SGAs, are reported in Table 4. SGAs were the most prescribed drugs in monopharmacy, with 28.6% of patients who did not assume other concomitant medications, except for benzodiazepines. At least one antidepressant was prescribed with SGAs in 9% of patients, followed by a mood stabilizer (7.6%) and one antidepressant plus a mood stabilizer (4.4%). FGAs were prescribed in monopharmacy in 9.4% of patients, without accounting for concomitant benzodiazepine prescriptions (given their higher prevalent coadministration in both APM and APP regimens). FGAs were administered with a mood stabilizer in 3.2% of patients, with at least one antidepressant in 3.1% of patients, or with their combination in 1.6% of patients treated with FGAs. Of note, 10.3% of patients were prescribed a combination of FGAs and SGAs alone, whereas 5.7 and 3.6% of patients received either a mood stabilizer or at least one antidepressant with an FGA plus SGA combination, respectively. The combination of the four drug categories was present in 0.8% of patients with SSDs.

**Physical activity**

The differences in physical activity levels between patients on APM, patients on APP and healthy controls are reported in Table 5. Out of 316 patients on APM and 291 patients on APP, 73 and 57 wore wearable accelerometers, respectively. Patients on APP wore wearable accelerometers for a shorter time than patients on APM and controls. Patients spent a significantly higher amount of time (minutes per day) being sedentary compared to controls. Among patients, those on APP were less sedentary than those on APM, although no significant differences were observed. The amount of time spent in light, moderate or vigorous physical activity was significantly different between patients and controls, with the latter performing more daily physical activity in each category of physical activity intensity. No significant differences in different physical activity intensity categories were observed between patients on APP and APM, although a trend of reduced sedentariness and higher light physical activity was observed for patients on APP than patients on APM. Even when looking at the mean METs per day, controls have significantly higher values, whereas no difference was observed between patients on different treatment regimens.

Figures 1–3 show the mean daily percentages of sedentary, light and moderate/vigorous physical activity, respectively, as assessed by accelerometers in patients on APM, patients on APP and controls during the week. The trend in the curves shows that light and moderate/vigorous physical activity levels are higher on weekdays, while they decrease at weekends. Sedentary levels, on the other hand, show an opposite trend.

**Discussion**

In this real-world, observational clinical study, we confirmed previous reports of a relevant rate of APP in patients with SSDs, with patients on APP showing higher disease severity than patients on APM. The relevant rate of APP was confirmed both in residential patients and outpatients, with the former being even more prone to polypharmacy than the latter. Residential patients were, as expected, more severely ill, and this may partly explain

| Table 4 Characteristics of polypharmacy among patients with schizophrenia spectrum disorders |
| --- |
| **N (%)** | 95% CI | Plus any benzodiazepine, N (%) | Plus any benzodiazepine, 95% CI |
| **First-generation antipsychotic** | | | |
| Alone | 58 (9.4%) | 7.1–11.7% | 27 (4.4%) | 2.8–6.0% |
| Mood stabilizer | 20 (3.2%) | 1.8–4.6% | 14 (2.3%) | 1.1–3.4% |
| At least one antidepressant | 19 (3.1%) | 1.7–4.4% | 12 (1.9%) | 0.9–3.0% |
| Antidepressant + mood stabilizer | 10 (1.6%) | 0.6–2.6% | 7 (1.1%) | 0.3–2.0% |
| **Second-generation antipsychotic** | | | |
| Alone | 177 (28.6%) | 25.0–32.1% | 62 (10.0%) | 7.6–12.4% |
| Mood stabilizer | 47 (7.6%) | 5.5–9.7% | 31 (5.0%) | 3.3–6.7% |
| At least one antidepressant | 56 (9.0%) | 7.2–10.8% | 31 (5.0%) | 3.3–6.7% |
| Antidepressant + mood stabilizer | 27 (4.4%) | 2.6–6.0% | 19 (3.1%) | 1.7–4.4% |
| **First- plus second-generation antipsychotic combination** | | | |
| Alone | 64 (10.3%) | 7.9–12.7% | 40 (6.5%) | 4.5–8.4% |
| Mood stabilizer | 35 (5.7%) | 3.8–7.5% | 23 (3.7%) | 2.2–5.2% |
| At least one antidepressant | 22 (3.6%) | 2.1–5.0% | 16 (2.6%) | 1.3–3.8% |
| Antidepressant + mood stabilizer | 5 (0.8%) | 0.1–1.5% | 5 (0.8%) | 0.1–1.5% |

*The column sum is not equal to 100% because 80 patients (12.9%) did not take first- or second-generation antipsychotics but were taking clozapine.

CI, confidence intervals; N, number.
Vigorous

mean % (SD) 5.1 (4.7) 4.0 (3.8) 7.5 (4.1)
mean % (SD) 0.7 (2.4) 0.4 (0.9) 3.8 (8.2)
mean % (SD) 0.1 (0.2) 0.0 (0.1) 0.3 (0.6)

Post-hoc tests summary

APP vs. APM
APP vs. HC
APP vs. HC

<0.001
<0.001
<0.001

<0.001
<0.001
<0.001

APP<APM/HC
APP<APM/HC
APP<APM/HC

Table 5 Differences in physical activity levels between patients (on antipsychotic mono- and polypharmacy) and healthy controls

|                     | Patients on APM | Patients on APP | HC                     | Post-hoc tests   |
|---------------------|-----------------|----------------|------------------------|------------------|
|                     | N=73(29.9%)     | N=57(23.4%)    | N=114(46.7%)           | P value*         |
|                     |                 |                |                        | APP vs. APM      |
|                     |                 |                |                        | APM vs. HC       |
|                     |                 |                |                        | APP vs. HC       |
| Wearing time (hour/day) | 22.3 (0.7)       | 21.7 (1.0)     | 22.5 (1.0)             | <0.001           |
| METs                | 1.4 (0.2)       | 1.4 (0.2)      | 1.6 (0.2)              | 0.002            |
| Sedentary (min/day) | 894.6 (150.5)   | 839.2 (138.6)  | 749.5 (134.7)          | <0.001           |
| mean % (SD)         | 66.2 (11.1)     | 63.9 (10.4)    | 54.7 (10.3)            | 0.993            |
| Light (min/day)     | 376.4 (116.8)   | 412.0 (115.1)  | 499.2 (113.1)          | 0.068            |
| mean % (SD)         | 28.6 (8.9)      | 32.0 (8.9)     | 37.5 (8.5)             | <0.001           |
| Moderate (min/day)  | 673.5 (82.5)    | 523.0 (50.1)   | 100.1 (55.1)           | <0.001           |
| mean % (SD)         | 5.1 (4.7)       | 4.0 (3.8)      | 7.5 (4.1)              | 0.291            |
| Vigorous (min/day)  | 0.7 (2.4)       | 0.4 (0.9)      | 3.8 (8.2)              | <0.001           |
| mean % (SD)         | 0.1 (0.2)       | 0.0 (0.1)      | 0.3 (0.6)              | 0.937            |

Post-hoc tests summary

APP<APM/HC
APP<APM/HC
APP<APM/HC

*Kruskal–Wallis test was performed for wearing time, METs, moderate and vigorous activities. ANOVA was performed for sedentary and light activities.

APP, antipsychotic polypharmacy; APM, antipsychotic monopharmacy; HC, healthy controls; N, number; min, minutes; METs, metabolic equivalent of tasks.

the higher rates of APP. The overall physical activity levels were significantly lower for all patients in our sample when compared to healthy controls. A trend of reduced sedentariness and higher levels of light physical activity was observed in patients on APP, which were more likely to live in psychiatric residential treatment facilities, vs. APM, possibly suggesting that rehabilitation efforts might be helpful in counteracting the generally reduced physical activity observed in patients compared to controls.

**Prescription patterns of psychotropic drugs**

Antipsychotics were the most commonly prescribed pharmacological class in our sample, as expected in patients with SSDs, with SGAs being the most commonly given prescription. In terms of the characteristics associated with APM and APP, our data showed that patients on APP had greater clinical severity, as evidenced by higher BPRS and BNSS scores and a lower level of psychosocial functioning as measured by the SLOF. This may suggest that, at least in some cases, there was an attempt by clinicians to manage the increased disorder severity by using the APP. However, following the prescription of a combination of antipsychotics is controversial. The negative symptoms, which were greater in the subsample of patients on APP, may have been both determined by the disorder itself or by the use of APP (Schooler, 1994; Artaloytia et al., 2006). Patients on APP were also more likely to have no partners, had a longer duration of illness and longer hospitalizations. When outpatients and residential patients were considered separately, APP was significantly more frequent in the latter, with FGAs and clozapine more frequently prescribed in this group of patients than outpatients. It is possible that the difference in prescribing patterns observed in our study between residential patients and outpatients is due, at least in part, to residential patients showing greater clinical severity than outpatients, echoing much of the differences between patients on APP and APM described above. Indeed, similarly to patients on APP, residential patients also showed higher psychopathological severity and worse psychosocial functioning, as well as longer hospitalizations (Martinelli et al., 2022).

Our results are largely in line with those of previous studies investigating differences between residential patients and outpatients (Auslander et al., 2001; Lee et al., 2019). Noteworthy, all of these characteristics, along with the aforementioned higher clinical severity, may have led to a worse response to treatments and may have prompted the use of drug associations, as suggested by previous studies (Bolstad et al., 2011; de Nijs et al., 2021; Oliva et al., 2022).

The second most prescribed drug class in our sample was benzodiazepines, which accounted for about 40% of prescriptions among outpatients and 70% among residential patients. Despite the wide use of this drug class in our sample, there is no consistent evidence to support the effectiveness of benzodiazepines in combination with APs on the core symptoms of SSDs. Therefore, their use should preferably be reserved by clinicians for short-term sedation of patients with acute agitation or for the treatment of AP-induced extrapyramidal effects (Dold et al., 2013; Pringsheim et al., 2018; Ekinci and Ekinci, 2022). The higher use of benzodiazepines among residential patients may be a consequence of greater disease chronicity, and a higher prevalence of extrapyramidal side effects related to a higher use of APP over time.

Interestingly, residential patients showed more associated comorbidities than outpatients in our sample, as
evidenced by higher CCI scores. The higher comorbidity index may have a close bidirectional link with polypharmacy. Indeed, polypharmacy may lead, among others, to an increased metabolic and cardiovascular risk, whereas the presence of multimorbidity may increase the risk of lower tolerability and safety profiles of pharmacotherapy (Misawa et al., 2011; Beauchemin et al., 2020; Guinart and Correll, 2020; Lin, 2020).

Physical activity and prescription of antipsychotic medications

Another aim of our study was to investigate the relationship between APM/APP and physical activity as measured by a wearable accelerometer-based biosensor. The overall physical activity levels were significantly lower for all patients in our sample compared to healthy controls, as expected, and the mean METs per day were significantly higher in controls than in patients, according to the higher levels of physical activity. The distribution of physical activity intensity among patients with SSDs, regardless of the prescribed antipsychotic therapy regimen, and controls in our sample was in line with previous evidence, which showed a pattern of less moderate physical activity and even less vigorous physical activity compared to healthy controls (Stubbs et al., 2016). Several previous studies have also evaluated physical activity in residential patients and outpatients, reporting low levels of physical activity in both groups and underlining the importance of implementing physical activity in both treatment settings. More in detail, studies conducted on large samples of residential patients found that 45% of them were inactive, not even taking part in household chores at their psychiatric residential treatment facilities (de Girolamo et al., 2005), and this finding was also confirmed by a more recent longitudinal study (de Girolamo et al., 2014). Similarly, outpatients showed higher levels of sedentary activity and lower levels of moderate and vigorous physical activity when compared to healthy age- and sex-matched controls (Soundy et al., 2013). Interestingly, we found a trend towards less sedentariness and a higher level of light physical activity in patients on APP compared to patients on APM. Given that patients on APP were more likely to live in psychiatric residential treatment facilities than those on APM, and because most psychiatric residential treatment facilities have a 24-h staff cover, it is possible that residential patients exhibited a trend of higher levels of light physical activity because they were more regularly stimulated by treating staff, as is also evident from previous studies (Mc Ardle et al., 2021). Furthermore, when physical health indices were considered, residential patients showed significantly lower BMI and waist circumference than outpatients, supporting our hypothesis of a 'compensatory'

---

**Fig. 1**

Percentage of Light Physical Activity (LPA) by group

Percentage of light physical activity as assessed by accelerometers in patients on antipsychotic monopharmacy, patients on antipsychotic polypharmacy, and healthy controls during the week. APM, antipsychotic monopharmacy; APP, antipsychotic polypharmacy; CI, confidence interval; HC, healthy controls.
contribution of rehabilitation programs in psychiatric residential treatment facilities, although it should also be considered that residential patients are usually subjected to a more supervised diet. Another explanation may be that patients on APP usually present more extrapyramidal side effects, such as akathisia (Pringsheim et al., 2018), and this may lead to persistent higher motor activity (Poyurovsky et al., 2000; Pieters et al., 2021).

Because the prescription of benzodiazepines was relatively high in our sample, it is interesting to briefly consider the relationship between this class of drugs and physical activity, even if it was not part of our primary objectives. Benzodiazepines use is known to be associated with sedation, poorer physical function and limitations in activities of daily living, as well as an increased risk of falls especially in the elderly, which together may lead to a reduction in daily physical activity (Gray et al., 2002; Donnelly et al., 2017; Wouters et al., 2020). The considerable use of benzodiazepines in the patients with SSDs in our sample may have further contributed to the lower physical activity levels observed in patients compared to healthy controls. Therefore, special attention must be paid to the management of benzodiazepine treatment in this complex patient population.

**Strengths and limitations**

Our study has some strengths but also limitations. Major strengths are the real-world design of this study, with the inclusion of both residential patients and outpatients, allowing an adequate snapshot of prescribing patterns of antipsychotics in Italy. Another major strength is the inclusion of a healthy control group, which allowed a useful comparison with the patient groups. Finally, the use of objective methods to assess physical activity instead of traditional self-reports, which are subject to reporting bias. Nevertheless, the current lack of standardized procedures for actigraphy measurements may have led to overestimates, limiting comparisons between different studies. We cannot rule out the negative effect of the restrictions imposed to contain the severe acute respiratory syndrome-coronaVirus 2 (SARS-CoV-2) pandemic, during which the recruitment took place, on the measured physical activity of outpatients and healthy controls. Other limitations included the lack of data about the individual molecule and long-acting antipsychotic prescriptions and prescribed drug doses. We did not apply a formal correction for multiple testing, as we started our analyses from a clear preplanned hypothesis with a clinical exploratory aim (Amrhein et al., 2019).
Conclusion
Overall, our study found high rates of APP in both patients living in psychiatric residential treatment facilities and outpatients diagnosed with an SSD, with a relatively higher prevalence of APP among residential patients, who were also those with greater clinical severity. Deviations from international prescribing guidelines may sometimes be justified by the need to control severe and residual symptomatology but may lead to worse physical health outcomes. Concerning physical activity, this was lower for all patients in our sample when compared to healthy controls, regardless of the antipsychotic treatment regimen prescribed to patients. However, it is possible that rehabilitation efforts in psychiatric residential treatment facilities led to trends of reduced sedentariness and higher light physical activity levels in residential patients than in outpatients, even though the former were more severely ill and polymedicated with antipsychotics. Our findings may have important clinical and public health implications, as they indicate the importance of implementing awareness programs aiming at reducing APP, when possible, to limit the occurrence of physical health problems, and active rehabilitation interventions to encourage physical activity among patients with SSDs.

Acknowledgements
The authors thank all members of the DiAPAsion Consortium who actively worked to make this project possible: Norbedo Alessandro and Paolo Peressutti (Department of Mental Health, ASUGI Trieste), Daniela di Cosimo (Fatebenefratelli di San Colombano al Lambro), Maria Concetta Miranda e Caterina D’anna (Department of Mental Health, ASL Napoli 2 Nord), Livia Fussi e Antonella Di Gregorio (Department of Mental Health, ASST Melegnano e della Martesana), Marzia De Santis (Department of Mental Health, ASL Roma1), Chiara Gibra e Elisabetta Pionetti (Department of Mental Health, ASST Lodi), Nicola Necchini e Valentina Regina (Psychiatric Clinic, University of Brescia), Cosima Calini e Anna Auxilia (Psychiatric Clinic, University of Milan-Bicocca), Annalisa Maurizi e Alessandro Bellotta (Comunità Passaggi, Oricola), Angelo Brega e Pasquale Di Prisco (Cooperativa “L’Incontro”, Castelfranco Veneto), Romina Ferretti (Department of Mental Health, ASL di Teramo), Giulio D’Anna e Lorenzo Tatini (Department of Mental Health, USL Toscana Centro), Michele Tosato (Department of Mental Health, ASL3 Genovese), Vera Abbiati e Silvia Bottura (Psychiatric Clinic, University of Pavia), Giorgio Gallino e Anna Myska (Department of Mental Health, ASL Città di Torino), Giuseppina Paulillo...
The DiAPASON (D’Aily time use, Physical Activity, quality of care and interpersonal relationships in patients with Schizophrenia spectrum disorder/s) Consortium includes: Arturo Rippa (Department of Mental Health, ASU Gi Trieste), Roberto Placenti (Fatebenefratelli di San Colombano al Lambro), Vittorio Di Michele (Department of Mental Health, ASL Pescara), Maria Gabriella Foa (Department of Mental Health, ASL Napoli 2 Nord), Federico Durbano (Department of Mental Health, ASST Melegnano e della Martesana), Tommaso Achille Poliseno (Department of Mental Health, ASL Roma1), Giancarlo Cerveri (Department of Mental Health, ASST Lodi), Michele Facchi (Psychiatric Clinic, University of Brescia), Rodolfo Pessina (Psychiatric Clinic, University of Milan-Bicocca), Filippo M. Jacoponi (Comunità Passaggi, Oricola), Roberto De Marchi (Cooperativa “Il Girasole”, Treviso), Patricia Giosuè (Department of Mental Health, ASL di Teramo), Andrea Baroncelli (Department of Mental Health, USL Toscana Centro), Lucio Ghio (Department of Mental Health, ASL di Torino), Lorenzo Pelizza (Department of Mental Health, AU SL di Parma), Valeria Latorre (Department of Mental Health, ASL di Bari).

The DiAPASON project is entirely funded by the Italian Ministry of Health (Bando per la Ricerca Finalizzata 2018: RF-2018-12365514). The Italian Ministry of Health organized the peer review of the study protocol to grant approval. The Italian Ministry of Health has no role in the analyses and interpretation of study findings.

The dataset referring to this manuscript is published with restricted access on the Zenodo platform at this link: https://doi.org/10.5281/zenodo.6651539.

Conflicts of interest
A. Serretti is or has been a consultant/speaker for Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier, and Taliáz. The other authors declare no conflicts of interest.

References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arntzen V, Greensland S, McShane B (2019). Scientists rise up against statistical significance. Nature 567:305–307.
Artaloya JF, Arango C, Lahtı A, Sanz J, Pascual A, Cubero P, et al. (2008). Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163:498–493.
Austadler LA, Lindamer LL, Delapena J, Harless K, Polichar D, Patterson TL, et al. (2001). A comparison of community-dwelling older schizophrenia patients by residential status. Acta Psychiatric Scand 103:380–386.
Beaucheimin, M. Geugchazde, R. Guntur AR, Nevola K, Le PT, Barlow, D, et al. (2020). Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications; risperidone alters the cardiac proteomic signature in mice. Pharmacol Res 152:104589.
Bellantuono C, Regg V, Tognoni G, Muscettola G. (1981). Comparison of practice in hospitals and community mental health centers. In: Epidemiological impact of psychotropic drugs. Elsevier, pp. 171–181.
Boistad A, Andreassen OA, Røesberg JI, Agartz I, Melle I, Tanum L (2011). Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia. BMC Psychiatry 11:126.
Caliskan AM, Karasilan M, Irani N, Caliskan S, Arslan M, Esra Cicek I, Eren I (2021). The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study. Int Clin Psychopharmacol 36:30–33.
Carton L, Cottencin O, Laperey-Mestre M, Geoffroy PA, Favre J, Simon N, et al. (2015). Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des 21:3280–3297.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383.
Chen LJ, Stepobo A, Chung MS, Ku PW (2016). Association between actigraphy-derived physical activity and cognitive performance in patients with schizophrenia. Psychol Med 46:2375–2384.
Cooper SJ, Reynolds GP, Barnes T, England E, Haddad PM, Head A, et al; With expert co-authors (in alphabetical order) (2016). BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 30:717–748.
Correll CU, Rummel-Klug C, Coves C, Kane JM, Leucht S (2009). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35:443–457.
De Berardis D, Vellante F, Formaro M, Orsolini L, Valchera A, Baroni G, et al. (2020). Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under piperazolone long-acting injection: a case report. Int Clin Psychopharmacol 35:113–118.
de Girolamo G, Williams P, Cappiello V (1987). Psychotropic drug utilization and audit in two Italian psychiatric services. Psychol Med 17:989–997.
de Girolamo G, Picardi A, Santone G, Falloni I, Morosini P, Fioritti A, Micciolo R; PROGRES Group. (2005). The severely mentally ill in residential facilities: a national survey in Italy. Psychol Med 35:421–431.
de Girolamo G, Candini V, Buizza C, Ferrari G, Boero ME, Gobbio GM, et al. (2014). Is psychiatric residential facility discharge possible and predictable? A multivariate analytical approach applied to a prospective study in Italy. Soc Psychiatry Psychiatr Epidemiol 49:157–187.
de Girolamo G, Rocchetti M, Benzi MA, Agosta S, Casiraghi L, Ferrari C, et al. (2020). Daily time use. Physical Activity, quality of care and interpersonal relationships in patients with Schizophrenia spectrum disorders (DiAPASON): an Italian multicentre study. BMC Psychiatry 20:287.
de Nijs J, Burger TJ, Janssen RJ, Kia SM, van Opstal DPJ, de Koning MB, et al; GROUP investigators. (2021). Individualized prediction of three- and six-year outcomes of psychosis in a longitudinal multicenter study: a machine learning approach. NPJ Schizophr 7:34.
Dold M, Li C, Gillies D, Leucht S (2013). Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23:1023–1033.
Donnelly K, Brachi R, Hewitt J, Routledge PA, Carter B (2017). Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PLoS One 12:e017430.
Ekinic O, Ekinic A (2022). Short-term, but not long-term, beneficial effects of concomitant benzodiazepine use on clinical course in patients with schizophrenia. Int Clin Psychopharmacol 37:143–150.
Estepes PS, Mota D, Cerejeira J, Mendes F (2015). Low doses of adjunctive aripiprazole as treatment for antipsychotic-induced hyperprolactinemia: a literature review. Eur Psychiatry 30:1–1.
Federici S, Meloni F, Mancini A, Lauriola M, Olivetti Belardinni M (2009). World health organisation disability assessment schedule II: contribution to the Italian validation. Disabil Rehabil 31:553–564.
Firth J, Stubbs B, Rosenbaum S, Vancampfort D, Malchow B, Schuch F, et al. (2017). Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull 43:546–556.
Firth J, Stubbs B, Vancampfort D, Schuch FB, Rosenbaum S, Ward PB, et al. (2018). The validity and value of self-reported physical activity and accelerometry in people with schizophrenia: a population-scale study of the UK biobank. Schizophr Bull 44:1293–1300.

Fisher MD, Reilly K, Isenberg K, Villa KF (2014). Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy. BMC Psychiatry 14:341.

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012). Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18–28.

Gallig B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012). Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression analysis. World Psychiatry 16:186–189.

Gold LH (2014). DSM-5 and the assessment of functioning: the World Health Organization disability assessment schedule 2.0 (WHODAS 2.0). J Am Acad Psychiatry Law 42:173–181.

Gray SL, LaCroix AZ, Blough D, Wagner EH, Koepsell TD, Buchner D (2002). Is age a correlate of antipsychotic polypharmacy: a systematic review and meta-regression analysis. World Psychiatry 16:186–189.

Guinart D, Correll CU (2020). Antipsychotic polypharmacy in schizophrenia: why not? J Clin Psychiatry 81:1101.

Gündoğmuş, I., Aydin MB, Öz S, Taşçı AB, Uzun Ö (2021). Clinical and demographic factors associated with early relapse in patients with schizophrenia: a naturalistic observation study. Int Clin Psychopharmacol 36:288–295.

Hildebrand M, VAN Hees VT, Hansen BH, Ekelund U (2014). Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc 46:1816–1824.

Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. (2009). Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiometabolic risk factors in healthy men and women: a meta-analysis. JAMA 301:2024–2035.

Lühteenmäki M, Tihonon J (2021). Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs 81:1273–1284.

Lee EE, Martin AS, Kaufmann CN, Liu J, Kangas J, Daly RE, et al. (2019). Comparison of schizophrenia outpatients in residential care facilities with those living with a study of mental and physical health, cognitive functioning, and biomarkers of aging. Psychiatry Res 275:162–168.

Lin SK (2020). Antipsychotic polypharmacy: a dirty little secret or a fashion? Int J Neuropsychopharmacol 23:125–131.

Lippi M, Fanelli G, Fabbri C, De Ronchi D, Serretti A (2022). The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? Int Clin Psychopharmacol. [Ahead of print].

Martellini A, Iozzino L, Pozzan T, Cristofalo D, Bonetto C, Ruggeri M (2022). Performance and effectiveness of step progressive care pathways within mental health supported accommodation services in Italy. Soc Psychiatry Psychiatr Epidemiol 57:939–952.

Mc Ardle R, Svedrup K, Del Din S, Lord S, Kerse N, Rochester L, Taylor L (2021). Quantifying physical activity in aged residential care facilities: a structured review. Ageing Res Rev 67:101298.

Migueles JH, Rowlands AV, Huber F, Sabia S, van Hees VT (2019). GGIR: a method for lifestyle effects?: a cross-sectional study. J Clin Psychiatry 81:431–440.

Montemagni C, Rocca P,ucci M, Galdi A, Serretti G, Maj M (2015). Italian version of the ‘Specific Level of Functioning’. J Psychopathol Behav 21:287–296.

Morosini PL, Casacchia M. (1995). Italian translation of the Brief Psychiatric Rating Scale, version 4.0 expanded (BPRS 4.0). Rivista di Riabilitazione Psichiatrica e Psicosociale 3:199–228.

Mucci A, Galderisi S, Merlotti E, Rossi A, Rocca P,ucchini M, et al; Italian Network for Research on Psychoses. (2015). The brief negative symptom scale (BNSS): independent validation in a large sample of Italian patients with schizophrenia. Eur Psychiatry 30:641–647.

Muscettola G, Bolin P, Pampallona S (1991). Pattern of neuroleptic drug use in Italian mental health services. DICP 25:296–301.

Muscettola G, Casiello M, Bolin P, Sebastiani G, Pampallona S, Tognoni G (1987). Pattern of therapeutic intervention and role of psychiatric settings: a survey in two regions of Italy. Acta Psychiatr Scand 75:55–61.

Oliva V, Fanelli G, Kasper S, Zohar J, Souery D, Montgomery S, et al. (2022). Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. Int Clin Psychopharmacol 37:38–45.

Overall JE, Gorham DR. (1962). The brief psychiatric rating scale. Psychol Rep 10:799–812.

Pieters LE, Deenik J, Tenback DE, van Oort J, van Herten PN (2021). Exploring the relationship between movement disorders and physical activity in patients with schizophrenia: an actigraphy study. Schizophr Bull 47:906–914.

Poyurovsky M, Nave R, Epstein R, Tzischinsky O, Schneidman M, Barnes TR, et al. (2000). Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia. Eur Neuropsychopharmacol 10:171–176.

Prince SA, Adamo KG, Hamel ME, Hart J, Connor Gorber S, Tremblay M (2008). A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act 5:56.

Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Riccieri L, et al. (2018). The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry 63:719–729.

Schooler NR (1994). Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand Suppl 380:21–26.

Simon GE, Stewart C, Yarborough BJ, Lynch F, Coleman KJ, Beck A, et al. (2018). Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry 75:254–260.

Soundy A, Wamper M, Probst M, De Hert M, Stubbs B, Vancampfort D, et al. (2015). Physical activity and sedentary behaviours in outpatients with schizophrenia: a systematic review and meta-analysis. Int J Ther Rehabil 20:588–595.

Strauss GP, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahen RP, et al. (2012). Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res 137:92.

Stubbs B, Firth J, Berry A, Schuch FB, Rosenbaum S, Gaughran F, et al. (2016). How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. Schizophr Res 176:431–440.

Tomasi R, de Girolamo G, Santone G, Picardi A, Micciolo R, Semisa D, Fava S; PROGRES Group. (2008). The prescription of psychotropic drugs in psychiatric residential facilities: a national survey in Italy. Acta Psychiatr Scand 113:212–223.

van Hees VT, Gorzenlak N, Deu Lewn EC, Eder M, Pias M, Taherian S, et al. (2013). Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity. PLoS One 8:e61691.

Vancampfort D, Probst M, Daenen A, Damme TV, De Hert M, Rosenbaum S, Bruyninckx D (2016). Impact of antipsychotic medication on physical activity and physical fitness in adolescents: an exploratory study. Psychiatry Res 242:192–197.

Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al. (2017). Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 16:308–315.

Walther S, Stegmayer K, Horn H, Ratsi N, Müller TJ, Strik W (2014). Physical activity in schizophrenia is higher in the first episode than in subsequent ones. Front Psychiatry 5:191.

Wong Z, Yong SWL, Chew OH, Guan C, Lee TS, Sim K (2019). Actigraphy studies and clinical and biobehavioural correlates in schizophrenia: a systematic review. J Neural Transm (Vienna) 126:531–558.

Wouters H, Hilmer SN, Twisk J, Teichert M, Van Der Meer HG, Van Hout HPJ, Taxis K (2020). Drug burden index and cognitive and physical function in aged care residents: a longitudinal study. J Am Med Dir Assoc 21:1086–1092.e1.